Skip to content

Toward an Ambitious National HIV/AIDS Strategy

  • Chad Cipiti

We won’t end HIV as an epidemic with anemic goals, delayed surveillance data, feeble support of state policies and resource needs, and an inadequate implementation science agenda By Kenyon Farrow The U.S. National HIV/AIDS Strategy (NHAS) ends its five-year run…

Read more

Ending the HIV Epidemic (ETE) in New York State

  • Chad Cipiti

Not only is it the right thing to do for the health of New Yorkers, but a new analysis demonstrates that it is also cost-effective By Ginny Shubert, Housing Works; and Mark Harrington In June 2014, New York Governor Andrew…

Read more

On Targets and Timelines

  • Chad Cipiti

By Tim Horn With growing recognition that science and discovery have forged the tools necessary to effectively diagnose, treat, and, indeed, eliminate three of the world’s most lethal infectious diseases—HIV/AIDS, tuberculosis, and hepatitis C—there is a need for greater mobilization…

Read more

TAGline Spring 2015

  • Chad Cipiti

On Targets and Timelines: With growing recognition that science and discovery have forged the tools necessary to effectively diagnose, treat, and, indeed, eliminate three of the world’s most lethal infectious diseases—HIV/AIDS, tuberculosis, and hepatitis C—there is a need for greater mobilization and strengthened accountability among all stakeholders.

Read more

Generics vs. the Giant

  • Chad Cipiti

For people with drug-resistant tuberculosis (DR-TB), generic linezolid may be a lifesaver. But only if quality-assured versions are available and affordable Erica Lessem As new drugs bedaquiline and delamanid offer renewed hope of treating DR-TB, doctors and programs are faced…

Read more

Safeguarding against Stock-Outs

  • Chad Cipiti

The time has come for U.S. tuberculosis programs to have full access to the Stop TB Partnership’s Global Drug Facility procurement and stockpile safety nets Kenyon Farrow Generic drugs can be credited with saving millions of lives by allowing for…

Read more

The Road to Treatment Access

  • Chad Cipiti

Generic drug registration, licensing, and a trip to Gilead’s islands Karyn Kaplan and Tracy Swan Access to essential medicines is part of the human right to health. The HIV/AIDS epidemic has demonstrated that generic competition is key to massive antiretroviral…

Read more

A Drug by Any Other Name

  • Chad Cipiti

The basics of generic medications, bioequivalence, and the push for good manufacturing practices Tim Horn Securing access to generic drugs to treat HIV, hepatitis C virus (HCV), and tuberculosis (TB) is now one of the most prominent strategies of global…

Read more

TAGline Fall 2014

  • Chad Cipiti

Hello Generics: A Drug by Any Other Name; The Road to Treatment Access; Safeguarding Against Stockouts; Generics vs. the Giant

Read more
Back To Top